NASDAQ:BNGO - BioNano Genomics Stock Price, News & Analysis

$1.82
+0.14 (+8.33 %)
(As of 08/16/2019 04:00 PM ET)
Today's Range
$1.60
Now: $1.82
$1.94
50-Day Range
$1.6781
MA: $2.43
$2.92
52-Week Range
$1.44
Now: $1.82
$10.00
Volume7,900 shs
Average Volume12,700 shs
Market Capitalization$19.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNGO
CUSIPN/A
CIKN/A
Phone858-888-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12 million
Book Value($0.12) per share

Profitability

Net Income$-18,500,000.00
Net Margins-247.03%

Miscellaneous

Employees77
Market Cap$19.84 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive BNGO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.


BioNano Genomics (NASDAQ:BNGO) Frequently Asked Questions

What is BioNano Genomics' stock symbol?

BioNano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

How were BioNano Genomics' earnings last quarter?

BioNano Genomics Inc (NASDAQ:BNGO) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.14. The firm had revenue of $2.18 million for the quarter, compared to analysts' expectations of $2.56 million. BioNano Genomics had a negative return on equity of 347.02% and a negative net margin of 247.03%. View BioNano Genomics' Earnings History.

When is BioNano Genomics' next earnings date?

BioNano Genomics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for BioNano Genomics.

What price target have analysts set for BNGO?

2 brokerages have issued 1 year price targets for BioNano Genomics' stock. Their predictions range from $7.00 to $12.00. On average, they anticipate BioNano Genomics' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 422.0% from the stock's current price. View Analyst Price Targets for BioNano Genomics.

What is the consensus analysts' recommendation for BioNano Genomics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNano Genomics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioNano Genomics.

What are Wall Street analysts saying about BioNano Genomics stock?

Here are some recent quotes from research analysts about BioNano Genomics stock:
  • 1. Maxim Group analysts commented, "Bionano reported 2Q19 with revenues of $2.2M and a net loss of ($7.7M). The company ended the period with $15.3M in cash on the balance sheet." (8/9/2019)
  • 2. According to Zacks Investment Research, "BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. " (7/8/2019)

Has BioNano Genomics been receiving favorable news coverage?

Press coverage about BNGO stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioNano Genomics earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for BioNano Genomics.

Are investors shorting BioNano Genomics?

BioNano Genomics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 5,000 shares, a decrease of 12.3% from the June 30th total of 5,700 shares. Based on an average daily volume of 14,200 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the company's shares are short sold. View BioNano Genomics' Current Options Chain.

Who are some of BioNano Genomics' key competitors?

What other stocks do shareholders of BioNano Genomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNano Genomics investors own include Arcadia Biosciences (RKDA), Mason Graphite (LLG), Agile Therapeutics (AGRX), Akari Therapeutics (AKTX), ArQule (ARQL), Alphatec (ATEC), Atossa Genetics (ATOS), AVEO Pharmaceuticals (AVEO), Axovant Gene Therapies (AXGT) and AXT (AXTI).

Who are BioNano Genomics' key executives?

BioNano Genomics' management team includes the folowing people:
  • Dr. Robert Erik Holmlin, Pres, CEO & Director (Age 51)
  • Mr. Michael J. Ward, Chief Financial Officer (Age 47)
  • Mr. Warren Robinson, Chief Commercial Officer (Age 50)
  • Mr. Mark Borodkin, Chief Operating Officer (Age 45)
  • Heather Adams, Sec.

When did BioNano Genomics IPO?

(BNGO) raised $16 million in an IPO on the week of August 20th 2018. The company issued 2,500,000 shares at $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are BioNano Genomics' major shareholders?

BioNano Genomics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sio Capital Management LLC (13.95%). Company insiders that own BioNano Genomics stock include Christopher J Twomey, David L Barker, Domain Partners Viii, LP, Mark Borodkin and R Erik Holmlin. View Institutional Ownership Trends for BioNano Genomics.

Which institutional investors are selling BioNano Genomics stock?

BNGO stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC. View Insider Buying and Selling for BioNano Genomics.

How do I buy shares of BioNano Genomics?

Shares of BNGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioNano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $1.82.

How big of a company is BioNano Genomics?

BioNano Genomics has a market capitalization of $19.84 million and generates $12 million in revenue each year. The company earns $-18,500,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. BioNano Genomics employs 77 workers across the globe.View Additional Information About BioNano Genomics.

What is BioNano Genomics' official website?

The official website for BioNano Genomics is http://www.bionanogenomics.com/.

How can I contact BioNano Genomics?

BioNano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company can be reached via phone at 858-888-7600 or via email at [email protected]


MarketBeat Community Rating for BioNano Genomics (NASDAQ BNGO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about BioNano Genomics and other stocks. Vote "Outperform" if you believe BNGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel